ライフサイエンスコーパス: RNase protection assay

1 ut changes in CRHR1 mRNA levels (measured by RNase protection assay).

2 art (Northern blot) and in liver and kidney (RNase protection assays).

3 day of a steroid-induced LH surge using the RNase protection assay.

4 ceptor gene expression was determined by the RNase protection assay.

5 profiles of selected genes were verified via RNase protection assay.

6 DEC205+B220+CD19- cells was demonstrated by RNase protection assay.

7 quantitative polymerase chain reaction, and RNase protection assay.

8 quantified in 1-week diabetic rats using the RNase protection assay.

9 by using RT-PCR and verified by sequence and RNase protection assay.

10 lial cells, and stromal fibroblasts with the RNase protection assay.

11 roups were then analyzed using a multi-probe RNase protection assay.

12 ption-polymerase chain reaction (RT-PCR) and RNase protection assay.

13 ) for GAD(65) mRNA determined by microlysate RNase protection assay.

14 mRNA expression was examined by quantitative RNase protection assay.

15 d by 5' rapid amplification of cDNA ends and RNase protection assay.

16 ified in the cells by both Northern blot and RNase protection assay.

17 expression of this gene was confirmed in an RNase protection assay.

18 Cytokine profiles were analyzed by ELISA and RNase protection assay.

19 Factor VIII-specific mRNA was measured by an RNAse protection assay.

20 L cells showed AQP1 transcript expression on RNase protection assay.

21 s and chemokine receptors were determined by RNase protection assay.

22 nd used to assess levels of IL-6 mRNA by the RNase protection assay.

23 ption-polymerase chain reaction (RT-PCR) and RNase protection assay.

24 imum of 164-fold after 8 h as measured by an RNase protection assay.

25 up) were analyzed for cytokine production by RNase protection assay.

26 one major initiation start site was found by RNase protection assay.

27 ith either MEV or ADV using a nonradioactive RNase protection assay.

28 nalyzed by using a sensitive strand-specific RNase protection assay.

29 rtum, the EOM MyHC RNA was first detected by RNase protection assay.

30 ression by liver DC subsets was evaluated by RNase protection assay.

31 ceptor (CCR) gene expression was analyzed by RNase protection assay.

32 ured mouse stromal fibroblasts by RT-PCR and RNase protection assay.

33 uence were suppressed by 86%, as detected by RNase protection assay.

34 lated by IFNgamma, and this was confirmed by RNase protection assay.

35 that induced by LPS in vivo, as measured by RNase protection assay.

36 t regulate chemokine gene induction using an RNase protection assay.

37 CAM)-1 were assessed at the RNA level of the RNase protection assay.

38 eron (IFN)-gamma and IL-10 was determined by RNase protection assay.

39 ified with SDS/PAGE and mRNA levels with the RNase-protection assay.

40 variants was confirmed by Northern blot and RNase protection assays.

41 o affect IL2R alpha expression, as judged by RNase protection assays.

42 gion of two RB69 target genes were mapped by RNase protection assays.

43 ected in lung tissue from challenged mice by RNase protection assays.

44 ine analysis, time resolved fluorometry, and RNase protection assays.

45 ly monocyte chemokine genes as determined by RNase protection assays.

46 in iris-ciliary body (I/CB) was analyzed by RNase protection assays.

47 site by rapid amplification of cDNA ends and RNase protection assays.

48 scence studies of retinal flat-mounts and in RNase protection assays.

49 t and neonatal and adult rat ventricle using RNase protection assays.

50 mental and control groups-were determined by RNase protection assays.

51 es, the gene chip findings were confirmed by RNase protection assays.

52 of HY-2 and HY-3 were evaluated by EMSA and RNase protection assays.

53 Defensin mRNA expression was quantitated by RNase protection assays.

54 alpha2-alpha4, alpha6, and beta2-beta4, with RNase protection assays.

55 te was identified using primer extension and RNase protection assays.

56 CP4 and ICP22/47 promoters, as determined by RNase protection assays.

57 ential expression of p96 was confirmed using RNase protection assays.

58 gene were identified by primer extension and RNase protection assays.

59 1, MIP-2, and IL-1R antagonist by RT-PCR and RNase protection assays.

60 ng, despite claims of its abundance based on RNase protection assays.

61 7 in a dose-dependent manner, as detected by RNase protection assays.

62 ines, receptors, and cell surface markers by RNase protection assays.

63 tify by reverse transcription-PCR and by the RNase protection assay a mRNA coding for a variant of ER

64 en receptor (TCR) beta-chain variable region RNase protection assays, after polymerase chain reaction

65 Multiprobe RNase protection assay also detected changes in the expr

66 T(2) RNase protection assays also demonstrated a fivefold dec

67 RNase protection assays also indicate that, at concentra

68 Consistent with the RNase protection assay, an increase in IL-8 protein was

69 -I/SkM2 mRNA in newborn rat brain using both RNase protection assay analysis and in situ hybridizatio

70 Cytokine expression was measured using RNase protection assay analysis in the eyeblink-trained

71 u hybridization and in adult rat brain using RNase protection assay analysis.

72 RNase protection assay and cell surface receptor analysi

73 mRNA levels were measured by RNase protection assay and DNA fragmentation by TUNEL as

74 Using the RNase protection assay and ELISA, little or no increase

75 Using the RNase protection assay and ELISA, we quantified expressi

76 HCV RNA and proteins were detectable by RNase protection assay and immunoblotting.

77 According to RNase protection assay and immunohistochemistry, iNOS mR

78 ected and uninfected ganglia by quantitative RNase protection assay and immunostaining.

79 The RNase protection assay and Northern blot analysis reveal

80 From RNase protection assay and RACE analysis, the major site

81 iction Landmark Genomic Scanning followed by RNase protection assay and reverse transcription-PCR to

82 lunteers was analyzed for SOCS expression by RNase protection assay and RT-PCR.

83 In addition, both the RNase protection assay and the 5'-RACE assay detected en

84 imilar increase in ecSOD mRNA as assessed by RNase protection assay and was prevented by losartan.

85 RNase protection assay and Western blot analysis reveale

86 Results from RNase protection assay and Western blot analysis showed

87 MCAF mRNA and protein was monitored with an RNase protection assay and Western blot analysis, respec

88 thelial cells (CECs) was determined using an RNase protection assay and Western blot analysis.

89 Further analysis by RNase protection assay and Western immunoblot demonstrat

90 ctomy and exogenous cortisol infusion, using RNase protection assays and a riboprobe containing exons

91 ned to be approximately 11 min by the use of RNase protection assays and an Escherichia coli model.

92 for the IL-12R beta 1 and beta 2 genes using RNase protection assays and assessed whether IL-12 induc

93 expression of MRP8 and MRP14 subunit mRNA by RNase protection assays and calprotectin complex by enzy

94 RNase protection assays and chemokine protein production

95 transcription-polymerase chain reaction and RNase protection assays and compared the results to telo

96 leased, and IL-8 expression was monitored by RNase protection assays and enzyme-linked immunosorbent

97 ne expression and secretion using multiprobe RNase protection assays and enzyme-linked immunosorbent

98 RNase protection assays and immunoblots revealed that An

99 RNase protection assays and in situ hybridization studie

100 nonspatial water tasks were determined using RNase protection assays and in situ hybridization.

101 However, RNase protection assays and kinetic studies suggest that

102 Hence, using RNase protection assays and ovine riboprobes, expression

103 RNase protection assays and plasminogen zymography showe

104 her these mRNA types were present in vivo by RNase protection assays and reverse transcriptase-mediat

105 RNase protection assays and RT-PCR confirmed microarray

106 channel expression by PDGF, as determined by RNase protection assays and whole-cell patch clamp recor

107 try, in situ hybridization and ribonuclease (RNAse) protection assays and function by in vitro chemot

108 ly spliced (apobec-T) mRNAs were measured by RNase protection assay, and apobec-T distribution was de

109 stological and immunohistochemical analyses, RNase protection assay, and flow cytometry of graft infi

110 hemokine genes was confirmed by quantitative RNase protection assay, and high secretion of chemokines

111 for transcription initiation, identified by RNase protection assay, and is sufficient for active tra

112 MCAF mRNA upregulation was confirmed by RNase protection assay, and MCAF protein was detected by

113 fication of cDNA ends PCR, RNA dot blotting, RNase protection assay, and Northern blot analysis.

114 NA (mRNA) was measured by Northern blotting, RNase protection assay, and real-time polymerase chain r

115 As assessed by northern hybridization, RNase protection assay, and reverse transcription-polyme

116 CrkIII at the message level using RT-PCR and RNAse protection assays, and at the protein level in mou

117 With RNase protection assays, and independently with inverse

118 al cells from arthritic paws was measured by RNase protection assays, and levels of cytokine protein

119 en activator inhibitor (PAI)-1 mRNA level by RNase protection assay at 1, 2, and 3 days after injecti

120 analysis, and displayed a Th 1 phenotype by RNase protection assay, but had a marked decrease in IL-

121 RNase protection assay confirmed the presence of an appr

122 PARgamma in skeletal muscle, and a sensitive RNase protection assay confirmed the presence of only PP

123 ultured from transgenic embryos, as shown by RNase protection assay, confocal microscopy, and ELISA.

124 In contrast to the E2F-3 polypeptide, RNAse protection assays demonstrate that the E2F-3 mRNA

125 RNase protection assays demonstrate three different prot

126 Northern blot and RNase protection assay demonstrated a 38% elevation in B

127 RNase protection assay demonstrated that 5 of 17 mutatio

128 RNase protection assay demonstrated that mechanical stra

129 In addition, RNase protection assays demonstrated that AP-2gamma was

130 analysis and quantitative measurements using RNase protection assays demonstrated that bcl-xL message

131 RNase protection assays demonstrated that Epo or dimethy

132 RNase protection assays demonstrated that IL-8 mRNA expr

133 RNase protection assays demonstrated that similar levels

134 RNase protection assays demonstrated that the expected e

135 RNase protection assays demonstrated that the flgE gene

136 RNase protection assays demonstrated that the NGF-induci

137 RNase protection assays demonstrated that transcription

138 RNase protection assay detected mRNA for PPARgamma1 but

139 tion of S.A.AR86-derived reporter assays and RNase protection assays determined that the presence of

140 The RNase protection assay displayed a single transcript fro

141 ng, real-time polymerase chain reaction, and RNase protection assay, each method has its own drawback

142 RNase protection assay, ELISA, and flow cytometry indica

143 Gene array data were confirmed using RNase protection assays, flow cytometry, and quantitativ

144 dial COX-2 mRNA levels (+231 +/- 64% at 1 h; RNase protection assay) followed 24 h later by an increa

145 Data from RNase protection assays, followed by the sequencing of m

146 To test this hypothesis, we developed RNase protection assays for specific detection of the in

147 RNase protection assays for the embryonic (Myh3) and ext

148 RNase protection assays further suggested that deletion

149 Using an RNase protection assay, globin mRNA species expressed in

150 RNase protection assays identified AKR1C1 (DD1) mRNA as

151 Analysis of RNase protection assays identified the transcription ini

152 ry, 5'-rapid amplification of cDNA ends, and RNase protection assays identified two populations of cD

153 ROS levels, and apoptosis were evaluated by RNase protection assay, immunoblot analysis, and ROS- an

154 easured expression of apoptotic molecules by RNase protection assay, immunofluorescence, and immunobl

155 re method to be superior to the conventional RNase protection assay in analyzing the cyclin E mRNA pr

156 , chemokines, and chemokine receptors by the RNase protection assay in chlamydia-pulsed dendritic cel

157 Expression was not detected by RNase protection assay in testis of vitamin A-deficient

158 on, ctxAB transcript levels were assessed by RNase protection assay in various vieSAB in-frame deleti

159 f-life of LTC4 synthase mRNA, as assessed by RNase protection assays in actinomycin D-treated cells.

160 a study using reverse transcription-PCR and RNase protection assays in transduced primary human fore

161 Changes in cytokine mRNAs (by RNase protection assay) in macrophages isolated by cell

162 ization and were examined by neuropathology, RNase protection assay, in situ hybridization, and in vi

163 RNase protection assays indicate that all of the newly g

164 RNase protection assays indicate that increased IL-8 rel

165 tomycin B (LMB) sensitivity experiments, and RNase protection assays indicate that RU5 gag RNA access

166 Quantitative RNase protection assays indicate that the SNV 5' RNA ter

167 alysis of the HN and L mRNAs by quantitative RNase protection assay indicated that the ratios of HN t

168 RNase protection assays indicated that human Ago2 intera

169 RNase protection assays indicated that nNOS mRNA (1) was

170 A, genomic Southern blots, RACE analysis and RNase protection assays, it appears that hFR-gamma share

171 Using RNase protection assays, it was documented that cocultur

172 ype distribution at mRNA and protein levels (RNase protection assays, ligand binding, contraction ass

173 As shown in RNase protection assays, LY294002 also inhibited insulin

174 By RNase protection assay, MAG mRNA was expressed in the He

175 Primer extension and RNase protection assays mapped the transcription initiat

176 s were independently confirmed by multiprobe RNase protection assay, Northern blotting, and reverse t

177 n and to optimize FIV-based vectors, we used RNase protection assays of cellular and virion RNAs to d

178 In addition, RNase protection assays of heterologous promoter/reporte

179 RNase protection assays of M1-D cellular RNA revealed up

180 evel of APN and NEP 24.11 were determined by RNase protection assays of RNA extracted from rat fronta

181 out thrombin for 4 h; and then processed for RNase protection assays of selected activation markers.

182 and chemokine mRNA levels were determined by RNase protection assays of total paw RNA.

183 evelopmental specificity, as demonstrated by RNase protection assays on multiple tissues from both fe

184 PTHrP mRNA levels, as measured in RNase protection assays, peaked at 2 h into the recovery

185 ity to detect ctaC-specific transcripts with RNase protection assays, primer extension, and rapid amp

186 sion and release was determined by ELISA and RNase protection assay, respectively, in peripheral bloo

187 cultured rat HSCs, as assessed by ELISA and RNase protection assay, respectively.

188 RNase protection assays reveal that erg message is found

189 P. gingivalis-infected HUVEC cultures by an RNase protection assay revealed an increase in the IL-8

190 In addition, RNase protection assay revealed increased whole lung exp

191 RNAse protection assay revealed significantly reduced ET

192 RNase protection assay revealed six major transcription

193 Use of a novel and highly sensitive RNase protection assay revealed striking muscle-specific

194 RNase protection assay revealed that in addition to CCL2

195 RNase protection assay revealed that radiation-induced e

196 A 3' RNase protection assay revealed that the 259 base and th

197 Furthermore, the RNase protection assay revealed the expression of multip

198 RNase protection assay revealed the induction of the pro

199 RNAse protection assays revealed elevated levels of mess

200 Indeed, RNase protection assays revealed increased expression of

201 RNase protection assays revealed increased levels of the

202 Northern analysis and RNase protection assays revealed low levels of Sebox RNA

203 RNase protection assays revealed that katA and bfrA are

204 Differential mRNA expression analysis and RNase protection assays revealed that macrophage inflamm

205 In vitro RNA binding and RNase protection assays revealed that RAP has an intrins

206 RNase protection assays revealed that the amount of Bcl-

207 S1 nuclease and RNase protection assays revealed the presence of multipl

208 Some changes were verified by an RNase protection assay, reverse transcription-PCR, immun

209 Gene expression studies using RNase protection assays, reverse transcription-PCR, and

210 -forming cells (ECFCs) was screened using an RNase protection assay (RPA) and 11 gene probes.

211 mRNA steady state amounts were determined by RNase protection assay (RPA) for IL-1alpha, IL-1beta, IL

212 mad signaling pathway we used a quantitative RNase protection assay (RPA) for measuring mRNA levels o

213 PP processing in the retina were examined by RNase protection assay (RPA), immunocytochemistry, immun

214 criptase polymerase chain reaction (RT-PCR), RNase protection assay (RPA), immunohistochemistry, and

215 Using a multi-probe RNAse protection assay (RPA), mRNA for 19 cytokines was

216 (S) and long (L) forms by northern blot and RNAse protection assay (RPA).

217 nd mRNA (trkB.FL) levels were measured using RNAse protection assay (RPA).

218 RNase protection assays (RPA) were used to determine if

219 dine incorporation assays and HIV-1-specific RNase protection assays (RPAs) indicate that translation

220 n, and VEGF mRNA levels were quantified with RNase protection assays (RPAs).

221 the conjunctiva and draining lymph nodes by RNase protection assay showed a profound decrease in the

222 An RNase protection assay showed approximately a 3-fold ind

223 RNase protection assay showed enhanced expression of poc

224 In addition, an RNase protection assay showed induction of mRNA of sever

225 An RNase protection assay showed that both TEF isoforms are

226 An RNase protection assay showed that the expression of the

227 RNase protection assays showed 4-5 different protected b

228 RNase protection assays showed a similar transcriptional

229 RNase protection assays showed positive- and negative-st

230 Northern blot and RNase protection assays showed that DL-homocysteine indu

231 RNase protection assays showed that LPS and MDP signific

232 RNase protection assays showed that mRNA for numerous ch

233 bridization with isoform-specific probes and RNase protection assays showed that the authentic, secre

234 RNase protection assays showed that the caspase-1, -2, -

235 RNase protection assays showed that two isoforms of the

236 RNase protection assays showed that ventricular expressi

237 ee LPA receptor subtypes (Edg2, -4, and -7); RNase protection assays showed the strongest expression

238 Ribonuclease (RNase) protection assays showed that ischemia increased

239 RNase-protection assays showed that in morpholino-inject

240 arison of elicited peritoneal macrophages by RNase protection assay shows an altered cytokine and cyt

241 RNase protection assay shows that alpha-enolase is trans

242 The RNase protection assay shows that HIV-1 U5-chloramphenic

243 oterless bicistronic constructs coupled with RNase protection assays, siRNA knockdown of individual c

244 both whole-mount in situ hybridizations and RNase protection assays, suggesting that carp is downstr

245 rol specimens was determined by a multiprobe RNase protection assay system.

246 We used an RNAse protection assay that permitted the simultaneous d

247 We show by RNase protection assays that transcripts encoding the Ig

248 We recently reported, based on an RNase protection assay, that human umbilical vein endoth

249 By RNase protection assays, the intergenic region is 292 ba

250 With the use of RNase protection assays, the ratio of hepatic PPAR alpha

251 Employing the primer extension and RNase protection assays, the transcription start site (d

252 We have used a quantitative RNase protection assay to characterize the relative accu

253 Here, we use an RNase protection assay to demonstrate that the mHuA tran

254 To test this hypothesis, we developed an RNase protection assay to directly measure the mRNA isof

255 To examine this hypothesis, we used RNase protection assay to measure mRNA levels of TRs in

256 e the kinetics of infection, we developed an RNase protection assay to quantitate gene expression fro

257 We have developed an RNase protection assay to quantitate intron RNA accumula

258 We have used reverse transcription-PCR and RNase protection assays to analyze the transcriptional s

259 Guinea-pig ventricle was used in the RNase protection assays to determine which alpha-isoform

260 diators involved in IRI, we used multi-probe RNase protection assays to examine the expression of 26

261 We also used RNase protection assays to measure NMDA receptor subunit

262 crucial leader-N gene junction, we employed RNase protection assays to precisely measure molar ratio

263 They were used for RNase protection assays to study the accumulation of ACC

264 Using 5'-rapid amplification of cDNA ends, RNase protection assays, transfection of cDNAs into FPGS

265 or in situ hybridization, Northern blot, and RNase protection assay using radiolabeled rat riboprobes

266 muscle and brain by RT-PCR and confirmed by RNAse protection assays using a 710 bp anti-sense RNA pr

267 RNase protection assays using a specific murine vascular

268 RNase protection assays using multi-template probes spec

269 The RNase protection assay was performed to confirm the init

270 RNase protection assay was used to assess the expression

271 RNase protection assay was used to measure altered gene

272 The level of bTERT, as quantitated by RNase protection assay, was not different between cancer

273 Using a multiprobe RNase protection assay, we examined cytokine and chemoki

274 Using an RNase protection assay, we found that IL-4 and IFN-gamma

275 nocytochemistry, electron microscopy, and an RNase protection assay, we observed that astrocytes supp

276 Finally, by RNase protection assay, we showed that the synthesis of

277 Via electrophoretic mobility shift and RNase protection assays, we demonstrate that bipartite a

278 Using RT-PCR and RNase protection assays, we detected Sck mRNA expression

279 With RNase protection assays, we determined that incubations

280 Using RNase protection assays, we determined that mast cells e

281 By RNase protection assays, we have assayed the effects of

282 Using RNase protection assays, we have determined that chronic

283 Using RNase protection assays, we have shown that patients hom

284 Using human cDNA arrays and ribonuclease (RNase) protection assays, we observed that VEGF up-regul

285 transcription-polymerase chain reaction and RNase protection assay were used to detect IGF-IR mRNA i

286 and gene fusions, Western analyses, and T(2) RNase protection assays were performed for strains with

287 As a final characterization, RNase protection assays were performed to examine expres

288 transcriptase-polymerase chain reaction and RNase protection assays were performed to examine proGnR

289 ith thyroid follicular cell TRAIL receptors, RNase protection assays were used to determine TRAIL mRN

290 RNase protection assays were used to examine a panel of

291 Multiprobe RNase protection assays were used to examine the transcr

292 hemokine receptor function using microarray, RNase protection assays, Western blot, and in vitro chem

293 sections were prepared from lung tissue for RNase protection assays, Western blotting, and in situ h

294 These results were confirmed by RNase protection assays which demonstrated a two- to thr

295 RNase protection assay with the use of a 32P-labeled ER-

296 RNase protection assay with various cell lines indicated

297 RNase protection assays with a probe for both C-CAM isof

298 Using RNase protection assays with a probe that distinguishes

299 With the use of RNase protection assays with probes representing 33 comm

300 collagen alpha1(I) mRNA level as measured by RNase protection assays, with maximal effects observed i